Drug Trial Radar · NCT07855692
The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Nov 5, 2026
Primary completion
May 31, 2029
Study completion Aug 31, 2029
Sponsor
- Lead sponsor
- Nagoya UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 26 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the effect of 12 weeks of treatment with tamibarotene compared with placebo on N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in patients with heart failure with preserved ejection fraction (HFpEF).
Conditions
- HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
TamibaroteneDrug
Tamibarotene 4 mg is administered orally once daily after breakfast for 12 weeks.
PlaceboDrug
Placebo is administered orally once daily after breakfast for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in serum NT-proBNPTime frame: Baseline, 4 weeks, 12 weeks, 16 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Juntendo University Hospital
Tokyo, Japan · Not yet recruiting
Nagoya University
Nagoya, Aichi-ken, Japan · Recruiting
National Center for Geriatrics and Gerontology
Ōbu, Aichi-ken, Japan · Not yet recruiting
Mie University Hospital
Tsu, Mie-ken, Japan · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.